PharmAthene to add antibody assets in Theraclone merger

Tools

Anthrax vaccine developer PharmAthene is to merge with antibody-focused biotech Theraclone Sciences. PharmAthene said the combined company will have four clinical-stage products, giving it the diversified portfolio desired by management. Article

Filed Under

Comments